Phase II study of interim FDG-PET-guided response-adapted therapy in pediatric patients with Hodgkin's lymphoma (HL-14)
- Conditions
- Hodgkin's lymphoma
- Registration Number
- JPRN-jRCTs041180174
- Lead Sponsor
- Koga Yuhki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 50
(1) diagnosis of Hodgkin's lymphoma
(2) age under 20 year old at diagnosis
(3) registration at JPLSG CHM-14 study
(4) written informed consent obtained from patient and/or guardians
(1) Cases where impaired liver, kidney and cardiac functions compromise experimental treatment
(2) Patients who have been treated with anticancer drugs or radiation therapy
(3) Presence of CNS degenerative lesion
(4) Associated intracranial hemorrhage which hinders execution of treatment process
(5) Associated infection which is difficult to control
(6) Pregnant or possibility of pregnancy
(7) Women who are breastfeeding
(8) Past history of malignant neoplasm or multiple primary neoplasms
(9) History of congenital or acquired immune deficiency syndrome
(10) Any other reasons that the attending physician has deemed unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method